Oncogenic mutations of ALK in neuroblastoma

Cancer Science

Volumn 102, Issue 2, 2011, Pages 302-308

  Ogawa, Seishi ^a,b   Takita, Junko ^a   Sanada, Masashi ^a   Hayashi, Yasuhide ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Gumna Children S Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CELL GROWTH; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FAMILIAL CANCER; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC DISORDER; GERM LINE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

ALLELES; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEUROBLASTOMA; PROTEIN-TYROSINE KINASES;

EID: 79952098597     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01825.x     Document Type: Review

References (74)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-20.
2. Hiyama E, Iehara T, Sugimoto T et al. Effectiveness of screening for neuroblastoma at 6months of age: a retrospective population-based cohort study. Lancet 2008; 371: 1173-80.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
4. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008; 9: 247-56.
5. De Bernardi B, Nicolas B, Boni L et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592-601.
6. Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-73.
7. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
8. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6.
9. Katzenstein HM, Bowman LC, Brodeur GM et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a pediatric oncology group study. J Clin Oncol 1998; 16: 2007-17.
10. Hansford LM, Thomas WD, Keating JM et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004; 101: 12664-9.
11. Mosse YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-5.
12. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-70.
13. George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-8.
14. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-4.
15. Friedman DL, Kadan-Lottick NS, Whitton J et al. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2005; 14: 1922-7.
16. Shojaei-Brosseau T, Chompret A, Abel A et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr Blood Cancer 2004; 42: 99-105.
17. Maris JM, Kyemba SM, Rebbeck TR et al. Molecular genetic analysis of familial neuroblastoma. Eur J Cancer 1997; 33: 1923-8.
18. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 1986; 57: 1887-93.
19. Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972; 24: 514-32.
20. Longo L, Panza E, Schena F et al. Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p. Hum Hered 2007; 63: 205-11.
21. Maris JM, Weiss MJ, Mosse Y et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res 2002; 62: 6651-8.
22. Perri P, Longo L, Cusano R et al. Weak linkage at 4p16 to predisposition for human neuroblastoma. Oncogene 2002; 21: 8356-60.
23. Amiel J, Laudier B, Attie-Bitach T et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 2003; 33: 459-61.
24. Mosse YP, Laudenslager M, Khazi D et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004; 75: 727-30.
25. Trochet D, Bourdeaut F, Janoueix-Lerosey I et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004; 74: 761-4.
26. Raabe EH, Laudenslager M, Winter C et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008; 27: 469-76.
27. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416: 153-9.
28. George RE, Attiyeh EF, Li S et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2007; 2: e255.
29. Nannya Y, Sanada M, Nakazaki K et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-9.
30. Yamamoto G, Nannya Y, Kato M et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-26.
31. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005; 167: 213-22.
32. Shiota M, Fujimoto J, Takenaga M et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994; 84: 3648-52.
33. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4.
34. Lee HH, Norris A, Weiss JB, Frasch M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003; 425: 507-12.
35. Stoica GE, Kuo A, Aigner A et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276: 16772-9.
36. Stoica GE, Kuo A, Powers C et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002; 277: 35990-8.
37. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20: 5623-37.
38. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439-49.
39. Morris SW, Naeve C, Mathew P et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-88.
40. Pulford K, Lamant L, Morris SW et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394-404.
41. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994; 9: 1567-74.
42. Lamant L, Pulford K, Bischof D et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000; 156: 1711-21.
43. Cools J, Wlodarska I, Somers R et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosom Cancer 2002; 34: 354-62.
44. Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 2000; 156: 781-9.
45. Ma Z, Cools J, Marynen P et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95: 2144-9.
46. Trinei M, Lanfrancone L, Campo E et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000; 60: 793-8.
47. Touriol C, Greenland C, Lamant L et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000; 95: 3204-7.
48. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59: 2776-80.
49. Bridge JA, Kanamori M, Ma Z et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001; 159: 411-5.
50. Ma Z, Hill DA, Collins MH et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosom Cancer 2003; 37: 98-105.
51. Panagopoulos I, Nilsson T, Domanski HA et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006; 118: 1181-6.
52. Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003; 83: 1255-65.
53. Jazii FR, Najafi Z, Malekzadeh R et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006; 12: 7104-12.
54. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-9.
55. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
56. Fujimoto J, Shiota M, Iwahara T et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A 1996; 93: 4181-6.
57. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997; 17: 2312-25.
58. Kuefer MU, Look AT, Pulford K et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90: 2901-10.
59. Chiarle R, Gong JZ, Guasparri I et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101: 1919-27.
60. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003; 22: 7750-61.
61. Soda M, Takada S, Takeuchi K et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008; 105: 19893-7.
62. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998; 18: 6951-61.
63. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000; 96: 4319-27.
64. Nieborowska-Skorska M, Slupianek A, Xue L et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 2001; 61: 6517-23.
65. Slupianek A, Nieborowska-Skorska M, Hoser G et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61: 2194-9.
66. Amin HM, McDonnell TJ, Ma Y et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-34.
67. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-83.
68. Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998; 273: 11987-90.
69. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117.
70. Galkin AV, Melnick JS, Kim S et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 2007; 104: 270-5.
71. McDermott U, Iafrate AJ, Gray NS et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-95.
72. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-22.
73. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-17.
74. Bang Y, Kwak EL, Shaw AT et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(Suppl): abstr3.